LC

Lyra Capital

North America, New York, United States, New York

Description

Lyra Capital is an investment firm.

Investor Profile

Lyra Capital has made 4 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (75%)
  • Debt Financing (25%)

Country Focus

  • United States (75%)
  • Canada (25%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Life Science
  • Enterprise Software
  • Hardware
  • Software
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Lyra Capital frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 2
Beedie Capital
North America, British Columbia, Canada, Vancouver
Co-Investments: 1
Hillhouse Investment
Asia, Central Region, Singapore, Singapore
Co-Investments: 2
RTW Investments
North America, New York, United States, New York
Co-Investments: 1
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 2
Lilly Asia Ventures
Asia, Shanghai, China, Shanghai
Co-Investments: 2
Boyu Capital
Asia, Beijing, China, Beijing
Co-Investments: 2

What are some of recent deals done by Lyra Capital?

Kailera Therapeutics

Waltham, Massachusetts, United States

Kailera Therapeutics is a clinical-stage biotechnology company that provides therapies for treating obesity and related diseases.

BiotechnologyPharmaceuticalTherapeutics
Series AOct 1, 2024
Amount Raised: $400,000,000
ArriVent Biopharma

Pennsylvania Furnace, Pennsylvania, United States

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

BiotechnologyLife SciencePharmaceutical
Series AFeb 15, 2022
Amount Raised: $69,000,000
ArriVent Biopharma

Pennsylvania Furnace, Pennsylvania, United States

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

BiotechnologyLife SciencePharmaceutical
Series AJun 30, 2021
Amount Raised: $81,000,000
Teradici

Burnaby, British Columbia, Canada

Teradici PCoIP technology drives all the components you need to run a remote desktop infrastructure, whether on premise or in the cloud.

Enterprise SoftwareHardwareSoftware
Debt FinancingFeb 19, 2016
Amount Raised: $10,000,000